{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:53:34Z","timestamp":1790391214542,"version":"4.1.0"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2505800"],"award-info":[{"award-number":["2022YFC2505800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2705005"],"award-info":[{"award-number":["2022YFC2705005"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0520706"],"award-info":[{"award-number":["2024ZD0520706"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32200651"],"award-info":[{"award-number":["32200651"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203776"],"award-info":[{"award-number":["82203776"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203125"],"award-info":[{"award-number":["82203125"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82222050"],"award-info":[{"award-number":["82222050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272739"],"award-info":[{"award-number":["82272739"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272882"],"award-info":[{"award-number":["82272882"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173287"],"award-info":[{"award-number":["82173287"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073003"],"award-info":[{"award-number":["82073003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003267"],"award-info":[{"award-number":["82003267"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002852"],"award-info":[{"award-number":["82002852"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373258"],"award-info":[{"award-number":["82373258"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82361168664"],"award-info":[{"award-number":["82361168664"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372980"],"award-info":[{"award-number":["82372980"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303873"],"award-info":[{"award-number":["82303873"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473396"],"award-info":[{"award-number":["82473396"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473038"],"award-info":[{"award-number":["82473038"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"publisher","award":["2021B1515230002"],"award-info":[{"award-number":["2021B1515230002"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"publisher","award":["2023B1515120092"],"award-info":[{"award-number":["2023B1515120092"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Program of Guangzhou","award":["202201011561"],"award-info":[{"award-number":["202201011561"]}]},{"name":"Science and Technology Program of Guangzhou","award":["2023A04J2127"],"award-info":[{"award-number":["2023A04J2127"]}]},{"name":"Science and Technology Program of Guangzhou","award":["2024B03J1248"],"award-info":[{"award-number":["2024B03J1248"]}]},{"name":"Sun Yat-sen University Clinical Research 5010 Program","award":["201315"],"award-info":[{"award-number":["201315"]}]},{"name":"Sun Yat-sen University Clinical Research 5010 Program","award":["2015021"],"award-info":[{"award-number":["2015021"]}]},{"name":"Sun Yat-sen University Clinical Research 5010 Program","award":["2017010"],"award-info":[{"award-number":["2017010"]}]},{"name":"Sun Yat-sen University Clinical Research 5010 Program","award":["2019023"],"award-info":[{"award-number":["2019023"]}]},{"DOI":"10.13039\/100020732","name":"Innovative Research Team of High-level Local Universities in Shanghai","doi-asserted-by":"publisher","award":["SSMU-ZLCX20180500"],"award-info":[{"award-number":["SSMU-ZLCX20180500"]}],"id":[{"id":"10.13039\/100020732","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Postdoctoral Innovative Talent Support Program","award":["BX20220361"],"award-info":[{"award-number":["BX20220361"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M763792"],"award-info":[{"award-number":["2024M763792"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Planned Science and Technology Project of Guangdong Province","award":["2019B020230002"],"award-info":[{"award-number":["2019B020230002"]}]},{"name":"Key Youth Teacher Cultivating Program of Sun Yat-sen University","award":["20ykzd24"],"award-info":[{"award-number":["20ykzd24"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The use of maintenance therapy for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) following first-line treatment with gemcitabine, cisplatin, and anti-PD-1 antibody remains controversial. Therefore, an effective and low-toxicity maintenance treatment option is urgently needed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study included 301 patients who received either combined maintenance therapy (anti-PD-1 antibody plus capecitabine) or anti-PD-1 antibody alone. Patients were matched in a 1:3 ratio using propensity score matching (PSM). Progression-free survival (PFS) was the primary outcome, and its association with maintenance therapy was assessed using the log-rank test and Cox proportional hazards model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifty-eight patients were included in the combined maintenance therapy group. After PSM, 174 patients were included in the anti-PD-1 antibody maintenance therapy group. In the matched cohort, the 2-year PFS rate was significantly higher in the combined maintenance therapy group than in the anti-PD-1 antibody monotherapy group (66.8% vs. 51.3%, P\u2005=\u2005.0063). Subgroup analysis showed that patients with pre-treatment Epstein-Barr virus (EBV) DNA\u2005&amp;gt;\u200512\u00a0400 copies\/mL and undetectable post-treatment levels had significantly improved PFS with combined maintenance therapy (hazard ratio [HR]\u2005=\u20050.44, 95% confidence interval [CI]\u2005=\u20050.20-0.96, P\u2005=\u2005.033). In contrast, no statistically significant PFS improvement from the combined maintenance therapy was observed among patients with low pre-treatment EBV DNA (\u226412\u00a0400 copies\/mL) and undetectable post-treatment levels (HR\u2005=\u20050.59, 95% CI\u2005=\u20050.27-1.27, P\u2005=\u2005.17), or those with detectable post-treatment EBV DNA levels regardless of pre-treatment levels (HR\u2005=\u20050.73, 95% CI\u2005=\u20050.31-1.70, P\u2005=\u2005.46). Combined maintenance therapy was associated with higher rates of grade 3-4 hand-foot syndrome (P\u2005&amp;lt;\u2005.001) and leukopenia (P\u2005=\u2005.0487).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Anti-PD-1 antibody plus capecitabine maintenance therapy improved PFS with manageable toxicities in patients with RM-MPC following first-line immunochemotherapy, particularly in those with pre-treatment EBV DNA &amp;gt;12\u00a0400 copies\/mL and undetectable post-treatment levels.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf188","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:35:41Z","timestamp":1750750541000},"source":"Crossref","is-referenced-by-count":1,"title":["Anti-PD-1 antibody with or without capecitabine as maintenance therapy after first-line therapy of recurrent or metastatic nasopharyngeal carcinoma"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7502-4784","authenticated-orcid":false,"given":"Yi-Fu","family":"Li","sequence":"first","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cheng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yi","family":"Shen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Anesthesiology, State Key Laboratory of Oncology in South China Sun Yat-sen University Cancer Center , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Wen","family":"Shen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Anesthesiology, State Key Laboratory of Oncology in South China Sun Yat-sen University Cancer Center , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Xiang","family":"Long","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Song","family":"Sun","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yun","family":"Peng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Guo","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9613-7305","authenticated-orcid":false,"given":"Lin-Quan","family":"Tang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Qiang","family":"Mai","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3533-9026","authenticated-orcid":false,"given":"Li-Ting","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]},{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"2025071710064157700_CIT0001","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"2025071710064157700_CIT0002","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025071710064157700_CIT0003","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025071710064157700_CIT0004","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of plasma epstein-barr virus DNA to screen for nasopharyngeal cancer","volume":"377","author":"Chan","year":"2017","journal-title":"N Engl J Med"},{"key":"2025071710064157700_CIT0005","article-title":"Head and neck cancers (Version 4.2025)","author":"National Comprehensive Cancer Network","year":"2025"},{"key":"2025071710064157700_CIT0006","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.22.00327","article-title":"Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial","volume":"40","author":"Zhang","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025071710064157700_CIT0007","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"2025071710064157700_CIT0008","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2015.08.003","article-title":"The prognostic value of plasma epstein-barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma","volume":"93","author":"Liu","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025071710064157700_CIT0009","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1200\/JCO.21.01467","article-title":"Deintensified chemoradiotherapy for pretreatment epstein-barr virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma: a phase II randomized noninferiority trial","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025071710064157700_CIT0010","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.annonc.2022.04.068","article-title":"Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma","volume":"33","author":"Chan","year":"2022","journal-title":"Ann Oncol"},{"key":"2025071710064157700_CIT0011","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/pathogens7020040","article-title":"The microenvironment in Epstein-Barr Virus-Associated malignancies","volume":"7","author":"Tan","year":"2018","journal-title":"Pathogens"},{"key":"2025071710064157700_CIT0012","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12032-015-0501-6","article-title":"Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma","volume":"32","author":"Zhang","year":"2015","journal-title":"Med Oncol"},{"key":"2025071710064157700_CIT0013","doi-asserted-by":"publisher","first-page":"10349","DOI":"10.1038\/s41598-017-10386-y","article-title":"The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9\/Tim-3-related changes in the tumour microenvironment","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"2025071710064157700_CIT0014","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41422-020-0374-x","article-title":"Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma","volume":"30","author":"Chen","year":"2020","journal-title":"Cell Res"},{"key":"2025071710064157700_CIT0015","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"key":"2025071710064157700_CIT0016","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"2025071710064157700_CIT0017","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025071710064157700_CIT0018","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"398","author":"Chen","year":"2021","journal-title":"Lancet"},{"key":"2025071710064157700_CIT0019","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1001\/jamaoncol.2022.4656","article-title":"Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a randomized clinical trial","volume":"8","author":"Miao","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025071710064157700_CIT0020","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jamaoncol.2021.7366","article-title":"Effect of capecitabine maintenance therapy plus best supportive care vs best supportive care alone on Progression-Free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy: a phase 3 randomized clinical trial","volume":"8","author":"Liu","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025071710064157700_CIT0021","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41467-024-45276-1","article-title":"Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial","volume":"15","author":"Cao","year":"2024","journal-title":"Nat Commun"},{"key":"2025071710064157700_CIT0022","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"2025071710064157700_CIT0023","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/cncr.20099","article-title":"Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A\/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma","volume":"100","author":"Shao","year":"2004","journal-title":"Cancer"},{"key":"2025071710064157700_CIT0024","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med"},{"key":"2025071710064157700_CIT0025","doi-asserted-by":"crossref","first-page":"110051","DOI":"10.1016\/j.radonc.2023.110051","article-title":"Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma","volume":"191","author":"Yu","year":"2024","journal-title":"Radiother Oncol"},{"key":"2025071710064157700_CIT0026","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamaoncol.2022.0122","article-title":"Effect of induction chemotherapy with paclitaxel, cisplatin, and capecitabine vs cisplatin and fluorouracil on Failure-Free survival for patients with stage IVA to IVB nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial","volume":"8","author":"Li","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025071710064157700_CIT0027","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12916-023-02790-1","article-title":"The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and\/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial","volume":"21","author":"Tang","year":"2023","journal-title":"BMC Med"},{"key":"2025071710064157700_CIT0028","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/hed.21884","article-title":"Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer","volume":"34","author":"Chua","year":"2012","journal-title":"Head Neck"},{"key":"2025071710064157700_CIT0029","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1517\/14656566.2014.866652","article-title":"Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy","volume":"15","author":"Gao","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"2025071710064157700_CIT0030","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.3390\/cancers13174399","article-title":"Capecitabine in combination with endocrine therapy as maintenance therapy after bevacizumab plus paclitaxel induction therapy for Hormone Receptor-Positive, HER2-Negative metastatic breast cancer: KBCSG-TR1214","volume":"13","author":"Masuda","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025071710064157700_CIT0031","doi-asserted-by":"publisher","first-page":"e1701","DOI":"10.1634\/theoncologist.2020-0577","article-title":"FOLFIRINOX De-Escalation in advanced pancreatic cancer: a multicenter Real-Life study","volume":"25","author":"Chevalier","year":"2020","journal-title":"Oncologist"},{"key":"2025071710064157700_CIT0032","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1007\/s00520-022-06859-0","article-title":"Modified docetaxel, cisplatin, and 5-fluorouracil combination regimen and capecitabine maintenance in metastatic gastric cancer: toxicity and efficacy results","volume":"30","author":"Arslan","year":"2022","journal-title":"Support Care Cancer"},{"key":"2025071710064157700_CIT0033","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/annonc\/mdw101","article-title":"Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety","volume":"27","author":"Luo","year":"2016","journal-title":"Ann Oncol"},{"key":"2025071710064157700_CIT0034","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.27990","article-title":"Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer","volume":"133","author":"Shevchenko","year":"2013","journal-title":"Int J Cancer"},{"key":"2025071710064157700_CIT0035","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"key":"2025071710064157700_CIT0036","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","article-title":"Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies","volume":"48","author":"Patel","year":"2018","journal-title":"Immunity"},{"key":"2025071710064157700_CIT0037","doi-asserted-by":"publisher","first-page":"e32542","DOI":"10.1371\/journal.pone.0032542","article-title":"Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells","volume":"7","author":"Wan","year":"2012","journal-title":"PLoS One"},{"key":"2025071710064157700_CIT0038","doi-asserted-by":"publisher","first-page":"e1438107","DOI":"10.1080\/2162402X.2018.1438107","article-title":"Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells","volume":"7","author":"Gravett","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025071710064157700_CIT0039","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025071710064157700_CIT0040","doi-asserted-by":"publisher","first-page":"e034010","DOI":"10.1136\/bmjopen-2019-034010","article-title":"Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review","volume":"10","author":"Li","year":"2020","journal-title":"BMJ Open"},{"key":"2025071710064157700_CIT0041","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s40425-019-0600-6","article-title":"First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy","volume":"7","author":"Zhou","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"2025071710064157700_CIT0042","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"2025071710064157700_CIT0043","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: The ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"2025071710064157700_CIT0044","doi-asserted-by":"publisher","first-page":"102123","DOI":"10.1016\/j.eclinm.2023.102123","article-title":"Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial","volume":"62","author":"Fang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025071710064157700_CIT0045","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/onco.13967","article-title":"Pathogenic DPYD variants and Treatment-Related mortality in patients receiving fluoropyrimidine chemotherapy: A systematic review and Meta-Analysis","volume":"26","author":"Sharma","year":"2021","journal-title":"Oncologist"},{"key":"2025071710064157700_CIT0046","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T&gt;G, c.1236G&gt;A\/HapB3, and c.1601G&gt;A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025071710064157700_CIT0047","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"key":"2025071710064157700_CIT0048","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025071710064157700_CIT0049","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025071710064157700_CIT0050","doi-asserted-by":"publisher","first-page":"e220587","DOI":"10.1001\/jamanetworkopen.2022.0587","article-title":"Association of plasma Epstein-Barr virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving Anti-Programmed cell death 1 immunotherapy","volume":"5","author":"Xu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025071710064157700_CIT0051","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejca.2021.05.022","article-title":"A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma","volume":"153","author":"Lee","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025071710064157700_CIT0052","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1002\/cam4.2926","article-title":"Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma","volume":"9","author":"Zhou","year":"2020","journal-title":"Cancer Med"},{"key":"2025071710064157700_CIT0053","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/cac2.12004","article-title":"The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: a propensity score matching study","volume":"40","author":"Sun","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"2025071710064157700_CIT0054","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"2025071710064157700_CIT0055","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2025071710064157700_CIT0056","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025071710064157700_CIT0057","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025071710064157700_CIT0058","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.radonc.2017.03.019","article-title":"Metastatic nasopharyngeal carcinoma: patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy","volume":"124","author":"Rusthoven","year":"2017","journal-title":"Radiother Oncol"},{"key":"2025071710064157700_CIT0059","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamaoncol.2020.1808","article-title":"Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial","volume":"6","author":"You","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025071710064157700_CIT0060","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/cncr.33984","article-title":"Long-term outcomes in patients with advanced and\/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: multicenter, real-world data (KCSG LU20-11)","volume":"128","author":"Kim","year":"2022","journal-title":"Cancer"},{"key":"2025071710064157700_CIT0061","doi-asserted-by":"publisher","first-page":"e001781","DOI":"10.1136\/jitc-2020-001781","article-title":"Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma","volume":"9","author":"Pokorny","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"2025071710064157700_CIT0062","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1200\/JCO.20.00131","article-title":"Continuous versus 1-Year Fixed-Duration nivolumab in previously treated advanced Non-Small-Cell lung cancer: CheckMate 153","volume":"38","author":"Waterhouse","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf188\/63612582\/oyaf188.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf188\/63612582\/oyaf188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf188\/63612582\/oyaf188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T14:06:49Z","timestamp":1752761209000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf188\/8176796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf188","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"oyaf188"}}